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Clinic addresses tumors
whose origins are unknown

Outwitting unknown primary tumors
Imagine treating a disease whose site, characteristics, and biological behavior are unknown. Without this knowledge, there is little basis for developing
a rational treatment plan or assessing its outcome.
But a small group of physicians at The University of
Texas M. D. Anderson Cancer Center are slowly
learning to overcome that uncertainty: they are
responsible for the care of the 200 to 300 patients
who come to M. D. Anderson each year with unknown primary tumor, a form of cancer that first
presents as the metastasis typical of late-stage cancer. About five percent of all cancers are unknown
primary tumors.
Martin N. Raber is
A typical cancer patient presents with signs and
chairman of the
symptoms of one tumor whose type and site can be
Department of Clinical
Investigations
ascertained. Determining the site of a tumor provides the physician with a large body of knowledge
that allows prediction of the tumor's behavior and
the patient's prognosis and thus development of a
treatment strategy. Unknown primary tumors, on
the other hand, provide too few clues for the physician to make these predictions.
"Unknown primary tumor" is a disquieting diagnosis to patients and physicians alike. It seems an
enigma that could be "known" if only the right test
were performed. Martin N. Raber, M.D., chairman
of the Department of Clinical Investigations, conceded that "physicians who are trained to base
James L. Abbruzzese is an
diagnosis and treatment on established patterns of
associate protessULof ______natural history 3L~e_a~y about unknown p ~
medicine in the Departtumors because these tumors are not only unprement of Gastrointestinal
.
.
Medical Oncology and
dictable but are notonously heterogeneous among
Digestive Diseases
patients."
Until 1987, when the Unknown Primary Tumor Clinic was founded at M. D. Anderson, little
attempt had been made to classify these patients or
to develop a treatment strategy for their disease.
Now, Raber and the other physicians of the clinic,
James L. Abbruzzese, M.D., chief of the Section of
General Oncology, and Renato Lenzi, M.D., assisTreatment Update

tant professor in the Section of General Oncology,
examine biological processes in these patients and
design individualized treatment strategies to outwit
the disease.

Clinical Investigations
M. D. Anderson has built a database of the more
than 1000 patients seen in the Unknown Primary
Tumor Clinic, and the physicians who treat these
patients have begun to construct the natural histories of unknown primary disease. Abbruzzese reported that an understanding of the prognostic
factors of unknown primaries is developing as the
clinic identifies subsets of patients who have responded similarly to treatments.
Raber explained that patients with unknown
primary tumor have neither a uniform prognosis
nor a uniform treatment course. Quite the contrary,
they have extremely varied outcomes, and for that
reason a major goal of the Unknown Primary Tumor Clinic is to sort patients. "There is danger,"
Raber emphasized, "in thinking that because the
group of patients having unknown primaries has a
poor prognosis that the individual does." Although
patients with· unknown primary tumors survive an
average of eight months from diagnosis, some survive as long as five years. Physicians at the clinic thus
try to identify favorable subsets ofpatients who have
diseases known to respond to certain treatments.
Although the amount of time that should be
spent searching for the site of the primary tumor is
controversial, Raber pointed out that the time is
minimized at M. D. Anderson because multidisciplinary evaluation by specialists in every field of
oncology is readily available; a complete, thorough
clinical evaluation requires only two to three days.
"As in many situations," commented Raber, "physicians who specialize in a disease have a different
view than do physicians who see it only rarely." All
patients in the Unknown Primary Tumor Clinic
continued on page 2
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"There is danger in thinking that because the group of
patients having unknown primaries has a poor
prognosis that the individual does."

undergo a physical examination, chest x-ray, computed tomographic scan of the abdomen and pelvis,
and routine screening for hematological and biological tumor markers. Gastrointestinal imaging,
thyroid screening, and specific tests are performed
if indicated by the findings of the first round of tests
or by patient complaints. Occasionally, pathologic
tests-light microscopy, immunohistochemistry, and
electron microscopy-on a tissue specimen reveal a
diagnosis that has previously been overlooked. Lenzi
added that the diagnosis of "undifferentiated carcinoma" is never accepted at M. D. Anderson: "When
a referring institution indicates this diagnosis, we
then perform various tests that help in making an
accurate diagnosis and in detecting tumors that are
potentially curable or responsive to treatment, such
as lymphomas and sarcomas."
For 75% of patients with unknown primaries,
tests are unable to detect the primary tumor. Although both the patient and the physician are more
comfortable with a specific diagnosis, researchers at
M. D. Anderson found that exhaustive searching
for the primary tumor does not guarantee a more
desirable outcome. In a study of 927 patients that
examined the value of each diagnostic test, the
investigators concluded that barium enemas and
upper gastrointestinal scans have a low yield in
finding primary tumors. To spare the patient unnecessary discomfort and expense, these tests are no
longer routine but are performed only for specific
indications.
Even so, physicians at M . D. Anderson agree
that _cancer can be managed on the basis of its
metastasized location. Lenzi observed, "Single-site
cancer requires regional surgery and radiotherapy
whether it is a primary site or a metastasized site,
and widespread disease requires systemic chemotherapy regardless of its point of origin." The histologic subtype of the disease and the metastasized
site of presentation are important criteria in determining treatment. Raber, concurring, voiced the
most essential questions: "What kind of cancer is it?
What are its pathologic characteristics?"
Patients whose primaries have not been determined are offered a chemotherapeutic protocol
developed for patients with unknown primary tumors, explained Raber. In developing the protocol,

consideration was given to the relative frequencies
of different sites in which unknown primaries are
thought to occur. At M. D. Anderson, the rate of
response to the regimen cisplatin plus 5-fluorouracil plus leucovorin is about 30%. Cisplatin was selected because it is effective in ovarian and lung
cancers, 5-fluorouracil and leucovorin because they
are effective in cancers of the gastrointestinal tract.
Because the new agent paclitaxel (Taxol) is thought
to be effective in breast, ovarian, and lung tumors
that are refractory to cisplatin, physicians at the
clinic have recently added it to the protocol.

Biological Investigations
A research team led by Menashe Bar-Eli, Ph.D.,
assistant professor of the Department of Cell Biology, hopes to describe the properties of the latestage metastatic cancers they find in patients with
unknown primary tumors. To explain the rapid
spread of the disease, the clinic is testing the hypothesis that unknown primary tumors are unique
and behave differently from known primary tumors.
Abbruzzese said, "Studies with mice indicate that
unknown primary tumors grow much more independently than do known primaries, suggesting
that these unknown tumors are much more 'malignant' in their ability to grow unrestrained and independently of their host." Abbruzzese said that this
postulate fits with the aggressive cancers and widespread metastases found in patients with unknown
primaries. Although some institutions have reported
that the path of metastasis in unknown primaries is
abnormal and that these cancers do not spread in
the same manner as known primaries, researchers at
M. D. Anderson have not found this to be so.
According to Lenzi, clinical studies show that the
spread of unknown primaries is similar to that of
known primaries-just faster.
The clinic has developed a number of cell lines
from patients with unknown primary tumors. Using these and other cancer cell lines, Bar-Eli is able
to compare the occurrences of common oncogenes,
thought to participate in the process of converting
normal cells into cancer cells, and tumor suppressor
genes (anti-oncogenes), thought to control the
growth and differentiation of tumors, in known and
unknown primary tumors. Bar-Eli said that his goal
continued on page 5
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Molecular technologies allow
development of biological agents

Biological response modifiers
promising adjuvants to cancer therapy
Physicians who look for new and better ways to
treat cancer patients have long recognized that the
body's natural immune system is a powerful fighter
of disease. Lacking the tools to harness that power,
they have relied largely on three treatment modalities: surgery, radiotherapy, and chemotherapy. Although these treatments, either alone or in
combinations, are effective in many patients, other
patients have little if any response to them. In
addition, some forms produce uncomfortable or
even unacceptably severe side effects or complications.
Today, however, new research tools have spawned
a vast new field of cancer therapy research. Biological therapy is a broad term encompassing the use of
various agents, most of them naturally occurring, to
induce or enhance the patient's own immune responses to disease. A few of these agents, or biological response modifiers, have been so clearly shown
effective in treating specific diseases that they have
already been approved by the U.S. Food and Drug
Administration for those applications. Most of these
agents, however, are still considered experimental.
Recombinant DNA technology ignites research
One of the most important of these tools is
recombinant DNA technology. This technique fuses
a gene that encodes a protein to a strand of DNA
from another organism; the DNA enables the gene
to make many copies of the protein, allowing mass
production of a relatively pure form of the protein.
The sudden availability of large amounts of many
bodily proteins fueled the explosion in molecular
biology and molecular genetics that has dominated
medicine for the last 15 years. As understanding of
the often multiple roles of these proteins in the
b~dy grew, cancer researchers began to develop
strategies for using them therapeutically, for example, to boost or substitute for the immune system. The field has moved rapidly: new models and
agents are being introduced ever more quickly, and
the strategies become more specific and more complex, utilizing combinations of agents and combinations of biological therapies with other modalities.
Recent figures show that the number of biological

therapies under investigation has exceeded the number of conventional chemotherapeutic drugs under
investigation.
The researchers and clinicians of the Department
of Clinical Immunology and Biological Therapy at
The University of Texas M. D. Anderson Cancer
Center are charged with investigating these agents
and incorporating them into therapeutic strategies.
In this, the first of a series of two articles, the
ongoing clinical trials of two important biological
therapies will be discussed.
Biological therapies ameliorate side effects of
other therapies
Saroj Vadhan-Raj, M.D., is looking for a way to
incorporate biological therapy into supportive
therapy, which aims to improve the effectiveness of
primary therapies such as chemotherapy and radiotherapy while enhancing the comfort and safety of
the patients receiving the therapy. Myelosuppression, the inhibition of the hematopoietic process of
generation, maturation, and functioning of blood
cells, is one of the most frequent and severe side
effects of chemotherapy and is often the reason that
chemotherapy dose is limited to a subtherapeutic
level. Hematopoietic suppression in cancer patients
may also be a response to internal disease processes.
Myelosuppression may lead to depletions of platelets and neutrophils and is the principal reason
patients receiving chemotherapy are especially prone
to infections and their complications, bleeding problems, and anemia.
Vadhan-Raj and her colleagues have for several
years studied the myeloprotective effects of hematopoietic growth factors, proteins that regulate
hematopoiesis and may indirectly trigger the release
of cytokines, which regulate communication between cells and the extracellular environment, mediating immune system responses. Vadhan-Raj
recalled, "In early trials, two factors called G-CSF
and GM-CSF were effective in accelerating neutrophil recovery from chemotherapy-induced myelosuppression, reducing the incidence of infections
and their sequelae by about 50%. This improvement was enough to allow modest elevation of the

Lab to Clinic

Saroj Vadhan-Raj is an
associate professor of
medicine in the Department of Clinical Immunology and Biological Therapy

James Lee Murray is a
professor of medicine in
the Department of Clinical
Immunology and Biological
Therapy

continued on page 4
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Recent figures show that the number of biological
therapies under investigation has exceeded the
number of conventional chemotherapeutic drugs
under investigation.

chemotherapy dose, but not enough to have a really
significant effect on tumor response. Nor did these
agents have any effect on thrombocytopenia or
anemia."
A more recent approach to myeloprotection has
been the combination of hematopoietic growth
factors. In this generation of trials, Vadhan-Raj and
her colleagues have tried combinations of G-CSF
and GM-CSF with several relatively newly discovered interleukins, substances that mediate immune
responses and are known to increase production of
platelets. These combinations have been more effective than the growth factors alone in reducing
myelosuppression.
Fusion molecule PIXY321 combines the
effects of two cytokines
The concept of combining cytokines has been
refined by fusing GM -CSF and an interleukin,
IL-3, in a molecule called PIXY321. The first phase
I clinical trial of PIXY32 l was conducted at M. D.
Anderson, and Vadhan-Raj and her colleagues from
the Department of Melanoma/Sarcoma Medical
Oncology found that PIXY32 l reduced the incidence and severity of not only neutropenia but also
thrombocytopenia in patients with sarcoma who
were receiving chemotherapy. In early trials,
PIXY321 appeared to reduce not only the incidence
and severity of myelosuppression, but also the incidence of infectious sequelae and the need for blood
transfusions. Moreover, the technique used to produce the fusion molecule has opened the door to
the development of customized combinations of
factors and other proteins that may offer even greater
therapeutic value. Vadhan-Raj hopes that this new
agent will be an important addition to the array of
therapies against myelosuppression. Phase II and
III trials are being planned.
Hematopoietic growth factors are also being
used to mobilize progenitor cells in peripheral blood,
another approach to overcoming myelosuppression
associated with high-dose chemotherapy. When
administered after chemotherapy in combination
with previously harvested and cryopreserved blood
progenitor cells, the growth factors enhance hematopoietic recovery from the chemotherapy, allowing higher doses. Another therapeutic approach

page 4

to myelosuppression is based on work carried out
by Vadhan-Raj and her colleagues on the proliferative kinetics of hematopoietic progenitor cells. In
these trials, growth factors are being used to stimulate cells to enter the cell cycle. When the therapy is
suddenly stopped, the cells enter the quiescent phase
of the cycle, which may protect them from the side
effects of chemotherapy. This technique attempts
to get as many cells as possible out of the S phase,
that is, to reduce their vulnerability to killing by
chemotherapy.
Vadhan-Raj and her colleagues are carrying on
with their work, trying newer, earlier acting growth
factors and techniques to prime target blood progenitor cells before treatment. These approaches
have great promise in providing complete hematopoietic reconstitution, allowing doses of chemotherapy that may offer substantial clinical benefit to
some patients.
Monoclonal antibodies attack tumors directly
James Lee Murray, M.D., is taking a more direct
approach: rather than providing supportive care for
a conventional treatment modality, he is using biological agents called monoclonal antibodies to attack tumors directly.
The concept of directing antibodies, either alone
or coupled to various toxic substances, as "magic
bullets" to tumor cells was first proposed in the
early 1900s. Because of the difficulties in obtaining
large enough quantities of these antibodies in a pure
enough form, little work was done to test this
concept until the mid-1970s, when the then-new
hybridoma technology, the fusion of normal mouse
lymphocytes and tumor cells, made it possible to
mass produce extremely pure mouse antibodies
derived from a single tumor cell, or clone. This
technology fueled the development of a group of
biological response modifiers known as monoclonal
antibodies, each of which targets a specific antigen.
Antibodies were first administered in their native, unaltered form to cancer patients. Many of the
antibodies are known to have their own immunologic activity: they not only "find" the tumor cells
in the body, but several of them directly mediate
killing of the cells. Despite the intuitive attractiveness of the approach, monoclonal antibodies have
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not yet found an established niche as anticancer
therapy. Murray recalled, "In the early 1980s, researchers began to realize that monoclonal antibodies administered alone were unlikely to eradicate
bulky tumors. They began designing studies that
combined antibodies with other biological response
modifiers or chemotherapeutic agents to enhance
their effects."
Conjugated antibodies effective in some solid
tumors
Monoclonal antibodies have been successfully
conjugated to substances known to kill tumors,
such as drugs, toxins, and radioisotopes. Radioisotope-antibody conjugates were the first to be used
in the clinic because they were the first conjugates
that did not lose the antibody's binding affinity for
the antigen. In early clinical trials, some of them at
M. D. Anderson, radiolabeled antibodies were
shown to effectively image tumor deposits. One
such antibody, Oncoscint™, has been approved by
the Food and Drug Administration to image ovarian or colon cancer.
· Various isotopes of higher radioactivities than
those used for imaging have been coupled to other
antibodies for use as radioimmunotherapy for can-

cer. Although these conjugates have yielded complete response rates as high as 70% in human lymphomas, they have been less effective in other solid
tumors, mainly because the radioactivities needed
to achieve the desired therapeutic effects cannot be
used because they are toxic to the bone marrow.
Researchers are looking at refinements of
radioconjugates that could deliver more radiation
to tumor sites while sparing normal organs.
Besides radioisotopes, both plant ( ricin) and
bacterial ( Pseudomonas) toxins have been used in
antibody conjugates. The most encouraging results
have been in leukemias or lymphomas: monoclonal
antibodies coupled to ricin have yielded response
rates of 40% to 50%.
Many investigators have been working primarily
with drug conjugates, the linking of a chemotherapeutic agent such as doxorubicin or vincristine to
the antibody. They have encountered a significant
problem: the linkers employed to connect the antibody to the drug reduce the potency of the antibody, the drug, or both. Moreover, the antibodies
that are produced from mouse cells, which include
most of those now in use, often stimulate the
production of antimouse antibodies in patients.
These antibodies may form immune complexes that
continued on page 7

Unknown Prim ary Tumors
continued from page 2

is to recognize a pattern of oncogene and antioncogene abnormalities that will allow speculation
about where an unknown primary tumor arose.
Bar-Eli also used these cell lines to study the
frequency of mutations in the tumor suppressor p53
gene in various tumor types. Because changes in
__p_53 usuall occur in the late sta es of man ' common adult primary cancers, just before they begin
to spread, it was expected that the highly metastatic
and advanced unknown primaries would have a
high incidence of p53 mutations. These mutations,
however, were found in only 26% of unknown
primaries, whereas they were found in 50% to 75%
of known primaries arising in the lung, breast,
pancreas, and gastrointestinal tract-sites frequently
found to be the origin of tumors initially considered
to be unknown primaries. Bar-Eli concluded that
p53 mutations do not play a major role in the
development and progression of these tumors.

Bar-Eli said, "This low frequency of mutations in
the p53 gene seemed to indicate that many unknown primary tumor cells progress to malignancy
through unique molecular changes." Bar-Eli and
Abbruzzese posited that although unknown primary tumors arise from a variety of primary sites
typical of known primary tumors, their highly aggressive biology suggests a unique series of molecu lar and biochemical events.
Because p53 mutations do not appear to play a
ma· or role in the metastases of unknown rimaries
M. D. Anderson investigators are searching for other
molecular markers that might explain the rapid metastasis. The clinic has begun screening patient tumors for K-ras, another gene mutated in many cancers.
Physicians who desire additional information may
write Dr. Raber, Department of Clinical Investigations, or Dr. Abbruzzese, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030, or call
(713) 792-7765 (Raber) or 792-2828 (Abbruzzese).

page 5

MD Anderson Oncolog

Synthetic Peptide
continued from page 8

the virus from binding to the receptors and penetrating the cell. Sastry is credited with creating
RlSK and discovering its inhibitory effects. He
likened the V3 loop to a key: when HIV, using the
V3 loop (the key), tries to enter a cell via a receptor
(the keyhole), it is unsuccessful because the entrance is already blocked by RlSK. "The theory
behind the peptide strategy is that the peptide and
the HIV V3 loop compete for cell-surface receptors, and the peptide wins," explained Sastry.
"We are not certain exactly how the peptide blocks
infection, but we believe it occupies all the sites on
the surface of the cell that the V3 loop might
otherwise use to allow the virus to enter the cell,"
he continued.
A very important step in the spread of HIV
infection is destruction of T cells by a process called
syncytium formation. In this process, an HIV-infected cell combines with several healthy T cells to
form a giant, multinuclear mass or syncytium. The
syncytia quickly die, killing the T cells. Sastry found
that the RlSK peptide can effectively block syncytium formation and prevent T cell loss.

Rl SK as treatment
Published studies suggest that at the time of
transmission and for a variable period afterwards,
HIV exists largely in nonsyncytial form and is
HIV-infected cell

Healthy T cells
fusing with
HIV-infected cell

~~

~ (•Y"':m fo•m=.

Syncytium
(giant cell)

Healthy T cells

0/:1
V3-loop (;, (;,

~m~:i

~

~

9

t/ !J -- tJ·~·"·
Syncytium formation is inhibited
by the R15K peptide

HIV is transmitted when infected cells attach to cell-surface receptors on healthy cells
(upper), forming giant, multinuclear masses, or syncytia. Rl SK blocks the virus's
pathway to the receptor (lower), preventing infection and protecting the cell.
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relatively harmless to the body's natural immune
system. It is believed that, during this phase, T cells
generated by the immune system keep the virus in
check. As the virus evolves, however, the immune
system becomes less able to combat the virus. The
result is the emergence of the syncytial form of HIV
and the onset of the illness phase, the point at which
the patient begins to develop AIDS.
The researchers anticipate that RlSK's infection-inhibiting activity could be used therapeutically to slow down or even stop the progression
from HIV infection to AIDS. Most therapeutic
strategies today employ reagents such as zidovudine
(AZT) to inhibit HIV once it has entered cells, but
the injection of RlSK into an HIV-infected individual would significantly slow down the virus's
evolutionary cycles, prolonging the patient's disease-free phase. "Our studies imply that RlSK
acts as an adjunct to the immune system, allowing
T cells to be more effective longer and delaying the
onset of AIDS," Arlinghaus commented.

RISK as vaccine
The M. D. Anderson team developed a new
vaccine approach that challenges the accepted
strategy and takes into consideration the unique
characteristics and behavior of HIV. "Traditional
thought dictates that antibody immunity is needed
to combat viruses," Arlinghaus stated. "But we
think HIV is structurally different from other viruses and that it reacts differently in ,the body.
We believe that to prevent HIV infection in hu mans, you have to induce a cellular immunity, a
killer T-cell immunity, without inducing anti-HIV
antibodies."
Arlinghaus believes that the team's novel strategy points to a breakthrough in HIV research. "The
vaccine community at large would probably still
consider this a 'dark horse' strategy, one that could
succeed but is by no means mainstream. However,
support-for our hypothesis is increasing. Several key
gures m e e o
vaccme researc are
beginning to seriously question the value of antibody immunity for HIV."
While investigating the preventive and therapeutic effects ofRlSK, Sastry discovered that RlSKhas
a significant third effect: it can induce a killer T-cell
response, a natural immune response that would
destroy cells already infected with HIV. Very little
is known about this effect, however. "This effect has
only been tested in mice. We have no data that
suggest that this response will occur in humans,
but we will continue to investigate this possibility,"
said Sas try.
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The next step: human trials
Two questions remain to be answered about the
effectiveness of Rl 5 K: Will the peptide work in
humans and, if so, can HIV, which is a shrewd
culprit, find another way to enter healthy cells? To
answer these questions, Sastry and his team will test
the effectiveness and safety of Rl 5Kin clinical trials
using human volunteers who are in the early stages
of HIV infection. Before conducting human trials,
tests will be conducted in animals to identify any
toxic effects the peptide may produce. The M. D.
Anderson research team will work with researchers
at The University ofTexas Medical School at Houston to obtain permission from the U.S. Food and

Drug Administration to conduct the clinical trials.
That approval could be granted within 12 months.
Arlinghaus added that if the peptide is successful
in treating HIV-infected humans, it may eventually
have a direct impact on cancers, such as B-cell
lymphoma and Kaposi's sarcoma, often found in
AIDS patients.
-VICKlE

J.

WILLIAMS

Physicians who desire additional information may write
to Dr. Sastry, Department of Molecular Pathology, The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030, or call
(713) 792-8995.

MD Anderson
Oncolog
The University of Texas
M . D. Anderson Cancer Center
President
Charles A. LeMaistre, M .D.
Vice President for
Academic Affairs

uses an "improved" chimeric antibody to reduce James M . Bowen, Ph.D.
Biological Response Modifiers
antigenicity and increase the likelihood of the anti- Associate Vice President
continued from page 5
body conjugate penetrating the tumor. Although for Academic Affairs
Robin R. Sandefur, Ph.D.
·some researchers believe chimeric antibodies will
• . .
bl
M
Director, Department
are cleared rapidly by the liver, deactivating the SO1Ve th e antigeruCity
pro em,
Urray expects tO
of Scientific Publications
drug conjugate. After a concerted effort, research- see antibodies fu.rther humanized-to about 98%, Walter J. Pagel
ers are now able to produce by recombinant mo- he estimated-nearly eliminating the chance of Editor
th
lecular techniques humanized or chimeric (part immunigenicity and increasing patient tolerance. Ka ryn L. Hale
Editors
mouse, part human) antibodies that can overcome This becomes especially important, explained Contributing
Vickie J. Williams
or minimize the problem of immunogenicity.
Murray, when multiple doses are desired.
Production
Murray also expects that monoclonal antibodi·es Yoshiko T. Ishida
BR96-doxorubicin conjugate in clinical trials will become smaller as a way to improve penetrabil- Photographs
One of the new and improved monoclonal anti- ity and facilitate manufacture. "Antibody fragments Donald c. Kelley
bodies is BR96. Developed by Bristol-Myers, BR96 offer hope in delivering more antibody to the tumor Editorial Board
David M . Gershenson, M.D.
binds strongly to Lewis y, a carbohydrate antigen and delivering it to the core of the tumor where it Frankie
A. Holmes, M.D.
found in large quantities on a number of tumors, can do the most good." Finally, he anticipates that Raymond E. Meyn, Jr., Ph.D.
William Plunkett, Ph.D.
including carcinomas of the colon, breast, pancreas, the antibodies will be manipulated to improve their Tyvin A. Rich, M .D.
S.
Eva Singletary, M .D.
and lung, some of the most prevalent and deadly targeting of and binding to the tumor antigen. Michael
J. Wargovich, Ph .D.
cancers. The conjugate of BR96 and the chemo"Right now," Murray states, "we need to focus the
· agent doxoru b'icm
· 1s,
· once bound to maJonty
· · o f our research euorts
Ir
·
·
th e
Published quarterly by the
therapeutlc
on 1mprovmg
Department of scientific
the tumor cell, readily internalized. The antibody therapeutic index of these antibodies that is on Publications, Division of Academic
'
'
Affairs, The University of Texas
- -----iih~asS"7.Jb~eeerrrr~'~'c1lmn·n1~1e~rr.iz~e~dt,~"1tl~1rat-rs:;-,n:acte-rrarttmrna:irr.-1 n·1crwUtt·rnz:~ei:r-anritumor e f f c - ~.-Arn~nn-f'"-;rni-..rl"=pn-j'P!'------1
.
I . nl
f .
1515 Holcombe Boulevard,
d amage to normal tissues. t 1s o ya matter o time Houston, Texas 77030 .
in an effort to diminish its immunogenicity.
In preclinical studies, BR96-doxorubicin signifi- before a new generation of antibodies will be ready Made possible by a gift from
cantly reduced the size oflarge solid tumors in mice for clinical testing."
the late Mrs. Harry C. Wiess.
-KATHRYN L. HALE
and rats, often curing the animals. Murray and
collaborators at M. D. Anderson and the University
of Alabama Cancer Center are conducting a phase Physicians who desire additional information may write
I clinical trial to determine the optimal dose, sched- Drs. Vadhan-Raj or Murray at the Department of Cliniule, and route of administration and the safety and cal Immunology and Biological Therapy, The University
of Texas M. D. Anderson Cancer Center, 1515 Holefficacy of the conjugate.
Although it is too early to report any results, combe Blvd., Houston, Texas 77030, or call (713) 7927966 (Vadhan-Raj) or 792-8189 (Murray).
Murray believes that this trial accurately reflects the
direction monoclonal antibody research is taking: it
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New agent may have both
preventive and therapeutic applications

Synthetic peptide effectively controls t
spread of HIV in human cell cultures
Cancer Prevention

Despite unprecedented biomedical research activity, a cure for the acquired immunodeficiency
syndrome, or AIDS, eludes investigators. Like all
infectious diseases, AIDS can be eradicated only by
a successful two-pronged strategy: prevention for
those who are likely to be exposed to the pathogen,
the human immunodeficiency virus (HIV), and
treatment for those who have already been infected.
a.oy
. . +-"-c"'"-'re.,__,_._atiY_e_approacbes ta prevention and treatment have been tried, and although some have
been successful in subpopulations of high-risk or
infected persons, the deadly disease remains a major
public health threat throughout the world.
Most experts agree that a fresh new approach is
needed, and that is exactly what a group of research-·
ers at The University of Texas M. D. Anderson
Cancer Center have developed. The new approach
is based on a synthetic peptide, a sequence of amino
acids that is part of a protein, that effectively inhibits
the spread of HIV in human cell cultures in the
laboratory. Although test tubes are a far cry from
human beings, the researchers are hopeful that the

- -l - - -----LL.l.....

K. Jagannadha Sastry is an
assistant professor in the
Department of Molecular
Pathology

peptide, kn n a RlSK an b de el p d into
both a accine that
uld pr nt HIV infection
and a drug that ould pr ent tran mi i n of the
infection.
Research on HIV began at M. D. And r on
Cancer Center i ear ago. Leadin th M. D .
Anderson re earch t am ar Ralph Arlinghau , Ph.D.,
professor and chairman, K. Jagannadha Sa try
?h-.D.,--assi tant--profo GF,--aAd Pramod Nehete,
Ph.D., research as ociate, all of th D partment of
Molecular Pathology.

Peptide blocks transmission of HIV
Infection occurs when HIV attaches to health
cells at cell-surface receptors through which the
virus is transmitted. Most researchers belie e that a
molecular component called the V3 loop on the
outer coat of HIV plays a critical role in the infection process. The M. D. Anderson researchers believe that RlSK, which is structurall similar to the
V3 loop, mimics the V3 loop in a wa that prevents
continued on page 6

